Analysts Lift Biogen Forecasts After Q1 Beat; Midyear BIIB080 Tau Data Loom
Biogen’s upbeat Q1 results drove analysts to raise EPS and revenue forecasts after the company reported stronger-than-expected growth driven by LEQEMBI and SPINRAZA uptake. Management highlighted upcoming midyear BIIB080 tau reduction data and potential Phase 3 readouts for LITIFILIMAB in SLE later this year.
1. Q1 Earnings and Analyst Revisions
Biogen delivered stronger-than-expected Q1 results with revenue growth driven by LEQEMBI and high-dose SPINRAZA uptake, prompting multiple analysts to raise full-year earnings and sales forecasts.
2. BIIB080 Tau Data Catalyst
Management reiterated that the BIIB080 antisense oligonucleotide targeting tau showed encouraging reductions in Phase 1b, with midyear proof-of-concept results set to reveal whether those reductions translate into cognitive benefits.
3. Pipeline and Biomarker Developments
Biogen expects two Phase 3 SLE readouts for LITIFILIMAB later this year, may pursue filing based on combined data, and noted that CMS approval of blood-based biomarkers is boosting LEQEMBI adoption. SYFOVRE’s significant lesion growth reduction and targeted ocular delivery underscore its competitiveness in geographic atrophy therapy.